| Cat. No. |
Product Name |
Information |
| PC-73081 |
Amphihevir
|
Amphihevir is a potent, selective HCV NS4B inhibitor with EC50 of 0.34 and 1.97 nM against the GT1a (H77) and GT1b replicon in luciferase assays. |
| PC-72892 |
Dichlorcyclizine
|
Dichlorcyclizine (DCCZ) is a potent, small molecule HCV fusion inhibitor, also inhibits SARS-CoV and SARS-CoV-2 S-mediated infection with EC50 of 9.92 and 4.53 uM, respectively. |
| PC-72891 |
Fluoxazolevir
|
Fluoxazolevir (NCGC00351982) is a potent, small molecule entry inhibitor of HCV with EC50 of 18.8 nM. |
| PC-72626 |
AT-527
|
AT-527 (AT527, Bemnifosbuvir hemisulfate, RG-6422) is a novel phosphoramidate prodrug of AT-511 that has potent in vitro activity against HCV (EC50=5-28 nM), also inhibits replication of SARS-CoV-2 with EC90 of 0.47 uM. |
| PC-63383 |
GSK-2878175
|
GSK-2878175 (GSK8175, GSK-175, GSK-175A) is a potent, pan-genotypic, second generation HCV NS5B palm polymerase inhibitor with EC50 of 0.4-9.7 nM. |
| PC-43099 |
Velpatasvir
|
Velpatasvir (GS-5816) is a second generation, pan-genotypic inhibitor of HCV NS5A, demonstrates a high barrier to resistance in HCV replicon assays.. |
| PC-63008 |
Radalbuvir
|
Radalbuvir (GS-9669) is a highly optimized thumb site II nonnucleoside inhibitor of HCV NS5B polymerase with binding affinity of 1.35 nM for genotype 1b. |
